News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK Cost Agency Says "No" To Bayer AG (BAYN.DE) Prostate Cancer Drug Xofigo


3/24/2014 7:01:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Britain's healthcare cost agency has recommended against using Bayer's new prostate cancer drug Xofigo on the state health service because the German firm did not provide evidence on how well it worked compared to other therapies. The draft guidance from the National Institute for Health and Care Excellence (NICE), issued on Monday, is now subject to consultation. "We are disappointed not to able to recommend this drug, but we have to be confident that its benefits justify its considerable cost," said NICE Chief Executive Andrew Dillon.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
Bayer AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES